J9
Glucocorticoid resistance inhibitor
Product Specifications
Background
J9, in combination with dexamethasone inhibits cell growth in T-cell acute lymphoblastic leukemia (T-ALL) through the upregulation of the glucocorticoid receptor. Patients can develop glucocorticoid resistance rendering the treatment ineffective. J9 and its mechanism of action provides a useful strategy for overcoming the resistance. The EC50 of J9 in combination with dexamethasone is 28 uM. J9 alone was less toxic.
Product Name Alternative
4-cyclopropyl-5- (pyridin-4-yl) pyrimidin-2-amine
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cancer | Cell Signaling | Epigenetics and Nuclear Signaling
Purity
99.9%
Weight
0.01
Format
White Solid
Solubility
Soluble in CDCI3
Molecular Formula
C12H12N4
Molecular Weight
212.26
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Cantley A.M., et al. (2014) ACS Medicinal Chemistry Letters 5.7: 754-759.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS8106185-01 0.1 mL
Recombinant Anti-FABP4 Antibody, Rabbit Monoclonal
Sign In for Pricing
View Details MBS8106185-02 5x 0.1 mL
Recombinant Anti-FABP4 Antibody, Rabbit Monoclonal
Sign In for Pricing
View Details 
E1872p 96 Tests
ELISA Kit For T-cell surface glycoprotein CD3 epsilon chain
Sign In for Pricing
View Details MBS1604029 96 Well
Human Anti Neuronal Nuclear Autoantibody 2, ANNA2 ELISA Kit
Sign In for Pricing
View Details